A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result

Prostate Cancer and Prostatic Diseases
M J DonovanG A Brown

Abstract

New screening methods that can add predictive diagnostic value for aggressive (high-grade, Gleason score ⩾ 7) prostate cancer (PCa) are needed to reduce unnecessary biopsies for patients with non-aggressive PCa. This is particularly important for men presenting for an initial biopsy with an equivocal PSA in the 2-10 ng ml(-1) range. PCA3 and ERG are biomarkers that can add predictive value for PCa in urine; however, with a limited utility as a digital rectal exam (DRE) is required. First-catch urine samples were collected at six sites from men scheduled to undergo a prostate biopsy. Exosomal RNA was extracted, RNA copy numbers of ERG and PCA3 were measured by reverse transcription-quantitative PCR (RT-qPCR), and the EXO106 score (the sum of normalized PCA3 and ERG RNA levels) was computed. Performance was compared with standard of care (SOC; PSA, age, race or family history) parameters. Contingency table, logistic regression, receiver operating characteristics curve and box-plot analyses were performed. In this cohort (N=195), a dichotomous EXO106 score demonstrated good clinical performance in predicting biopsy result for both any cancer and high-grade disease. For high-grade disease, the negative and positive predictive value...Continue Reading

References

Jun 20, 2003·European Urology·Daphne HesselsJack A Schalken
May 28, 2004·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Apr 20, 2006·Journal of the National Cancer Institute·Ian M ThompsonCharles A Coltman
Aug 15, 2006·Current Treatment Options in Oncology·Laurence Klotz
Oct 25, 2006·Neoplasia : an International Journal for Oncology Research·Bharathi LaxmanArul M Chinnaiyan
Feb 18, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin R RiceShiv Srivastava
Apr 30, 2010·Kidney International·Kevin C MirandaLeileata M Russo
May 10, 2011·Cellular and Molecular Neurobiology·Kristan E van der VosXandra O Breakefield
Jul 20, 2012·The New England Journal of Medicine·Timothy J WiltUNKNOWN Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group
Jun 22, 2013·European Urology·Stacy LoebYair Lotan
Nov 12, 2013·The Journal of Urology·Siebren DijkstraJack A Schalken
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Feb 13, 2014·Applied Immunohistochemistry & Molecular Morphology : AIMM·Maria A SvenssonMark A Rubin
Mar 7, 2014·The New England Journal of Medicine·Anna Bill-AxelsonJan-Erik Johansson
Apr 15, 2014·The Urologic Clinics of North America·Marc A BjurlinSamir S Taneja
Apr 15, 2014·The Urologic Clinics of North America·David M Berman, Jonathan I Epstein
May 13, 2014·The Journal of Urology·Karl-Johan LundströmAnna Bill-Axelson
Jul 27, 2014·The Journal of Urology·Franck BruyèrePatrick Coloby

❮ Previous
Next ❯

Citations

Apr 2, 2016·The Journal of Clinical Investigation·Carla Zijlstra, Willem Stoorvogel
Mar 1, 2016·European Urology·Kerstin JunkerGuido Jenster
Aug 16, 2016·Clinics in Laboratory Medicine·Lindsay N Strotman, Mark W Linder
Nov 29, 2015·The Urologic Clinics of North America·Michael S Leapman, Peter R Carroll
Oct 30, 2016·International Journal of Molecular Sciences·Xavier Filella, Laura Foj
Apr 5, 2017·Prostate Cancer and Prostatic Diseases·V R MinciacchiD Di Vizio
Mar 17, 2017·Molecular Diagnosis & Therapy·Irene V BijnsdorpElena S Martens-Uzunova
Dec 22, 2016·Molecular Diagnosis & Therapy·Michael J Donovan, Carlos Cordon-Cardo
Jun 8, 2018·Biotechnology Journal·Donatella LucchettiAlessandro Sgambato
Dec 21, 2017·Prostate Cancer and Prostatic Diseases·Stephen J Freedland
May 21, 2019·BJU International·Shea P ConnellJeremy Clark
Jun 5, 2019·Journal of the National Cancer Institute·Jouhyun JeonPaul C Boutros
Jan 19, 2019·Prostate Cancer and Prostatic Diseases·Jillian N EskraJun Luo
Nov 14, 2019·Abdominal Radiology·Amihay NevoPaul Andrews
Dec 13, 2019·Nature Reviews. Urology·Johannes Linxweiler, Kerstin Junker
Jun 18, 2020·Cancers·Felipe CouñagoElia Del Cerro
Jul 24, 2020·Current Opinion in Urology·Stephan BrönimannShahrokh F Shariat
Sep 5, 2020·Expert Review of Molecular Diagnostics·Fernando López-CamposFelipe Couñago
Jan 24, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Xiangju Liu, Ming Xue
May 5, 2018·International Journal of Urology : Official Journal of the Japanese Urological Association·Fumihiko UrabeTakahiro Ochiya
Jun 29, 2018·Frontiers in Oncology·Virginie Vlaeminck-Guillem
Apr 25, 2019·International Journal of Molecular Sciences·Indu KohaarShiv Srivastava
Aug 15, 2018·Current Urology Reports·James T Kearns, Daniel W Lin
Apr 19, 2018·Cellular Oncology (Dordrecht)·Vignesh SundararajanThamil Selvee Ramasamy
Sep 10, 2019·Expert Review of Molecular Diagnostics·Philip ZeuschnerKerstin Junker
Oct 28, 2020·Journal of Korean Medical Science·Jae Hoon ChungSeong Soo Jeon
Jan 1, 2021·Investigative and Clinical Urology·Jeong Hyun Kim, Sung Kyu Hong
Apr 2, 2021·Journal of Medical Internet Research·Rossana CastaldoMonica Franzese
May 1, 2021·International Journal of Molecular Sciences·Stefano SalcicciaMartina Maggi
May 22, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Michael P RimmerRod T Mitchell
Jun 3, 2021·Cancers·Lidia BorkiewiczIlona Telejko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.